首页> 外文会议>PEGS >Cancer Immunotherapy Based on Engineered Novel Antibodies to Treat Cancers and Build Better Therapeutics

【24h】

Cancer Immunotherapy Based on Engineered Novel Antibodies to Treat Cancers and Build Better Therapeutics

机译：基于工程新的抗体治疗癌症的癌症免疫疗法，并建立更好的治疗方法

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

Cancer immunotherapy based on monoclonal antibodies (mAbs) are enjoying unprecedented success, and owing to their superior antigen-binding affinity and specificity, mAbs have been approved for the treatment of various types of cancers in clinic. By using a large human antibody library and phage display technologies, we have identified various mAbs and small-sized novel antibodies against emerging infectious diseases and cancers. The aim of the study is focus on the various approaches to using mAb-based therapeutics to treat cancers and building better mAb-based treatments.

机译：基于单克隆抗体（mAb）的癌症免疫疗法享有前所未有的成功，并且由于其优异的抗原结合亲和力和特异性，MAb已被批准用于治疗临床中的各种类型的癌症。通过使用大型人类抗体库和噬菌体展示技术，我们已经确定了各种MAB和小型新型抗体免受新出现的传染病和癌症。该研究的目的是专注于使用基于MAB的治疗方法治疗癌症和建立更好的MAB的治疗方法的各种方法。

著录项

来源
《PEGS》|2016年|CD-ROM ;|共1页
会议地点
作者
Yanling Wu; Tianlei Ying;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类生物工程学（生物技术）;
关键词

相似文献

外文文献
中文文献
专利

1. Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates [J] . Dalenc Florence, Sarradin Victor, Nicolai Vincent, Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer . 2021,第1期

机译：三重阴性转移性乳腺癌最近的治疗趋势：PARP抑制剂，免疫疗法和抗体 - 药物缀合物
2. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A [J] . Marcin Kowanetz, Christina Rabe, Yuanyuan Xiao, Journal for ImmunoTherapy of Cancer . 2014,第S3期

机译：循环和基于肿瘤的生物标志物预测用工程化抗PD-L1抗体MPDL3280A治疗的癌症患者的临床活动
3. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A [J] . Marcin Kowanetz, Christina Rabe, Yuanyuan Xiao, Journal for ImmunoTherapy of Cancer . 2014,第S3期

机译：循环和基于肿瘤的生物标志物预测用工程化抗PD-L1抗体MPDL3280A治疗的癌症患者的临床活动
4. Cancer Immunotherapy Based on Engineered Novel Antibodies to Treat Cancers and Build Better Therapeutics [C] . Yanling Wu, Tianlei Ying PEGS . 2016

机译：基于工程新颖的抗体治疗癌症的癌症免疫疗法，并构建更好的治疗方法
5. Using the allergic immune system to target cancer: Tumor specific IgE antibodies as cancer therapeutics [D] . Teo, Zhao Ying Pearline 2008

机译：使用过敏性免疫系统靶向癌症：肿瘤特异性IgE抗体可作为癌症治疗剂
6. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A [O] . Marcin Kowanetz, Christina Rabe, Yuanyuan Xiao, 2014

机译：循环和基于肿瘤的生物标志物预测用工程化抗PD-L1抗体MPDL3280A治疗的癌症患者的临床活动
7. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A [O] . 2014

机译：循环和基于肿瘤的生物标志物预测用工程化抗PD-L1抗体MPDL3280A治疗的癌症患者的临床活动
8. Neural Stem Cell Delivery of Therapeutic Antibodies to Treat Breast Cancer Brain Metastases [R] . Felding-Habermann, B. 2010

机译：用于治疗乳腺癌脑转移的治疗性抗体的神经干细胞递送

Cancer Immunotherapy Based on Engineered Novel Antibodies to Treat Cancers and Build Better Therapeutics

摘要

著录项

相似文献

相关主题

期刊订阅